Neutrolis

Immunology & Inflammation Therapeutics · Biotechnology

Overview

Targeting the Dark Side of DNA. Neutrolis aims to transform the lives of patients with autoimmune and inflammatory diseases by degrading neutrophil extracellular traps (NETs), removing the root cause of disease without relying on immunosuppression.

Visa sponsorship

United StatesUS 0
0
H-1B filings in 12 months
0
Open roles in United States
In the register as Neutrolis Inc., Cambridge, MA
Other sponsors in the same field
Daiichi Sankyo 28 filingsCuria 23 filingsKashiv Biosciences 17 filingsAldevron 11 filings
Alert me
US Department of Labor · latest filing Jun 16, 2025 · Visa details by country

Financials

Total raised
$28.1M
Latest round
Convertible Note
Funding rounds
5
Funding rounds
Round Announced Amount
Convertible Note 2025 $3.5M Details
Venture - Series Unknown 2025 $965k Details
Venture - Series Unknown 2021 $23.1M Details
Grant 2020 $210k Details
Grant 2020 $252k Details

People

Abdul Rahamathullah
Director, Executive Officer
SEC Form D
Toby Fox
Director, Executive Officer
SEC Form D
Anthony Aiudi
Director, Executive Officer
SEC Form D
Gerald Chan
Director
SEC Form D
John Sundy
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge United States
HQ
Scientific and Medical Advisory Board
50-200 est. staff
Cambridge, MA 02142
company site